Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Trial TRAX Multiple Sclerosis Clinical Trial Monitoring Brief

Published by: Austin Research Group

Published: Oct. 1, 2007


Table of Contents


Section 1: Executive Summary

Multiple Sclerosis Disease Overview: Background

Clinical Courses of Multiple Sclerosis

Clinical Endpoints in Multiple Sclerosis Trials

Overview of Clinical Landscape

Key Players in Multiple Sclerosis R&D

Competitor Clinical Trial MAP-The Orals

Competitor Clinical Trial MAP-Biologics

Section 2: Ongoing Clinical Trial in Rheumatoid Arthritis

Phase I & Phase II: Competitive Clinical Trial Details

Phase III: Competitive Clinical Trial Details

Phase IV: Competitive Clinical Trial Details

Section 3: Appendix

Disclaimer

Report Licensing

Abstract

The Multiple Sclerosis (MS) therapeutic market will experience a significant shift in power in the next five years. The current market leaders, Interferons and Copaxone, could lose their dominance to novel orally formulated and biologic treatments that offer superior convenience, efficacy, and quality of life for MS patients. The strong trend in the increased competitiveness of the oral class is also validated by the R&D efforts of the MS market leader, Biogen Idec (Avonex), who is investing heavily in 2 programs for oral drugs in phase 2 (CDP-323) and phase 3 (BG-12).

It is critical that stakeholders currently competing or considering entry into this hyper-competitive therapeutic market are well-informed with the latest intelligence on clinical trials of competitors of today and the future.

Austin Research Group’s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease including:
  • Epidemiology
  • Patient Segmentation
  • Clinical endpoints
The Trial TRAX brief also contains analysis of the clinical landscape which comprises assessments including:
  • % utilization of key clinical endpoints
  • Number of ongoing trials (by phase of development)
  • Key companies sponsoring clinical trials
Key data points from competitor clinical trials presented in the briefing include:
  • Study Drug
  • Mechanism of Action
  • Company-Sponsor
  • Phase of Development
  • Number of Patients
  • Study Design
  • Primary Endpoints
  • Study Start Date
The brief’s reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs. The information contained within the report is updated on a quarterly basis to ensure accuracy, relevancy, and timeliness of the intelligence.

Clients utilize the Trial TRAX briefing reports to: Monitor clinical development programs of competitors Evaluate depth and breadth of competitive landscape Identify potential patient recruitment challenges Benchmark competitor clinical trial designs

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008